---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-296577"
form_type: "8-K"
ticker: "SLDB"
cik: "0001707502"
company_name: "Solid Biosciences Inc."
filed_at: "2022-12-01T23:59:59+00:00"
generated_at: "2026-06-21T10:58:27.910772+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Solid Biosciences stockholders approve share issuance for AavantiBio merger and amended equity plan

## Summary
- Stockholders approved issuance of shares for the acquisition of AavantiBio under the Merger Agreement (4,054,470 for, 41,480 against).
- Approved amended 2020 Equity Incentive Plan, increasing share reserve by 866,666 to 1,533,333 shares plus annual evergreen 5% of outstanding shares.
- Equity plan proposal passed with 3,480,064 for and 614,534 against.
- Annual increase feature begins fiscal year 2023 up to fiscal 2032 at Board discretion.
- Approval removes key condition for closing the AavantiBio acquisition.

## SEC filing metadata
- accession: 0001193125-22-296577
- form_type: 8-K
- ticker: SLDB
- cik: 0001707502
- company_name: Solid Biosciences Inc.
- filed_at: 2022-12-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 5.07, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/0001193125-22-296577-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/d430820d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-296577
- JSON: https://secwatch.observer/filing/0001193125-22-296577.json
- Plain text: https://secwatch.observer/filing/0001193125-22-296577.txt

## Key facts
- Shareholder Votes
  Solid Biosciences Inc. shareholders approved To approve issuance of shares pursuant to the Merger Agreement and Securities Purchase Agreements.
  - Proposal: merger approval
  - Outcome: passed
  source text: 1. The Share Issuance Proposal . To consider and vote upon a proposal to approve, for purposes of Nasdaq Listing Rule 5635, the issuance of shares of the Company’s common stock pursuant to the terms of the Agreement and Plan of Merger, dated September 29, 2022, by and among the Company, Greenland Merger Sub LLC, AavantiBio and, solely in his capacity as equityholder representative, Doug Swirsky (the “Merger Agreement”) and the Securities Purchase Agreements, dated September 29, 2022, by and among the Company and several accredited investors named therein (the “Securities Purchase Agreement”) (such proposal, the “Share Issuance Proposal”). Votes For Votes Against Abstentions 4,054,470 41,480 7,054
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/0001193125-22-296577-index.htm
- Shareholder Votes
  Solid Biosciences Inc. shareholders approved To approve the adoption of the Amended and Restated 2020 Plan to increase the number of shares issuable thereunder.
  - Proposal: equity plan
  - Outcome: passed
  source text: 2. The Equity Incentive Plan Proposal . To consider and vote upon a proposal to approve the adoption of the Amended and Restated 2020 Plan to, among other things, increase the number of shares issuable thereunder. Votes For Votes Against Abstentions 3,480,064 614,534 8,406
  evidence_url: https://www.sec.gov/Archives/edgar/data/1707502/000119312522296577/0001193125-22-296577-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.